-

QuidelOrtho Appoints Lee Bowman as Chief Human Resources Officer

SAN DIEGO--(BUSINESS WIRE)--QuidelOrtho Corporation (Nasdaq: QDEL) is pleased to announce the appointment of Lee Bowman as Chief Human Resources Officer (CHRO). In this pivotal role, Bowman leads QuidelOrtho’s human resources strategy, driving initiatives that bolster a dynamic and inclusive workplace culture. Bowman reports to Brian Blaser, President and Chief Executive Officer.

Bowman brings over 25 years of experience in human resources leadership, with a distinguished career that spans key roles in major industries. Most recently, he served as the Senior Vice President and Chief People Officer at RadNet, a leading healthcare technology company, where he led transformative initiatives in workforce engagement, diversity and inclusion, and leadership development. His career also includes significant contributions at Edwards Lifesciences, Levi Strauss & Co., and Target, where he led high-impact HR strategies that prioritized team development and organizational growth.

“Lee is an exceptional leader with a deep understanding of how to align human resources strategies with business objectives,” said Brian Blaser, President and Chief Executive Officer of QuidelOrtho. “His expertise in talent development and commitment to fostering an inclusive, high-performing workplace will be pivotal as we continue to strengthen our team and drive continued growth.”

As CHRO, Bowman oversees all facets of QuidelOrtho’s human resources function, including the design and implementation of strategies across compensation, benefits, recruitment, talent management, training and employee development.

Bowman holds an MBA from San Diego State University and a Bachelor of Science from Towson University.

QuidelOrtho is dedicated to advancing diagnostics to power a healthier future. For more information, please visit www.quidelortho.com and follow QuidelOrtho on LinkedIn, Facebook and X.

About QuidelOrtho Corporation

QuidelOrtho Corporation (Nasdaq: QDEL) is a world leader in in vitro diagnostics, developing and manufacturing intelligent solutions that transform data into understanding and action for more people in more places every day.

Offering industry-leading expertise in immunoassay and molecular testing, clinical chemistry and transfusion medicine, bringing fast, accurate and reliable diagnostics when and where they are needed – from home to hospital, lab to clinic. So that patients, clinicians and health officials can spot trends sooner, respond quicker and chart the course ahead with accuracy and confidence.

Building upon its many years of groundbreaking innovation, QuidelOrtho continues to partner with customers across the healthcare continuum and around the globe to forge a new diagnostic frontier. One where insights and solutions know no bounds, expertise seamlessly connects and a more informed path is illuminated for each of us.

Contacts

Investor Contact:
Juliet Cunningham
Vice President, Investor Relations
IR@QuidelOrtho.com

Media Contact:
D. Nikki Wheeler
Senior Director, Corporate Communications
Media@QuidelOrtho.com

QuidelOrtho Corporation

NASDAQ:QDEL

Release Versions

Contacts

Investor Contact:
Juliet Cunningham
Vice President, Investor Relations
IR@QuidelOrtho.com

Media Contact:
D. Nikki Wheeler
Senior Director, Corporate Communications
Media@QuidelOrtho.com

More News From QuidelOrtho Corporation

QuidelOrtho to Participate in Upcoming Investor Conferences

SAN DIEGO--(BUSINESS WIRE)--QuidelOrtho Corporation (Nasdaq: QDEL) (“QuidelOrtho”), a global provider of innovative in vitro diagnostic technologies designed for point-of-care settings, clinical labs and transfusion medicine, announced today that members of its management team will participate in two upcoming investor conferences: William Blair 45th Annual Growth Stock Conference, Wednesday, June 4, 2025 Members of QuidelOrtho’s management team will participate in a presentation at 9:00 a.m. ET...

QuidelOrtho Reports First Quarter 2025 Financial Results

SAN DIEGO--(BUSINESS WIRE)--QuidelOrtho Corporation (Nasdaq: QDEL) (the “Company” or “QuidelOrtho”), a global provider of innovative in-vitro diagnostic technologies designed for point-of-care settings, clinical labs, and transfusion medicine, today announced financial results for the first quarter ended March 30, 2025. “We delivered solid first quarter performance driven by growth in our Labs business and the strength of our recurring revenue business model,” said Brian J. Blaser, President an...

QuidelOrtho to Report First Quarter 2025 Financial Results

SAN DIEGO--(BUSINESS WIRE)--QuidelOrtho Corporation (Nasdaq: QDEL) (the “Company”) or (“QuidelOrtho”), a global provider of innovative in-vitro diagnostic technologies designed for point-of-care settings, clinical labs and transfusion medicine, announced today that it will report its financial results for its first quarter 2025 ended March 30, 2025, after the market close on Wednesday, May 7, 2025. Following the release of financial results, QuidelOrtho will hold a conference call beginning at...
Back to Newsroom